Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intec Pharma Ltd.NTEC · Entity 146542 | Director | July 15, 2020 | July 17, 2020 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 09, 2026 |
| Travere Therapeutics, Inc.RTRX · Entity 1562 | Director | May 08, 2019 | May 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intec Pharma Ltd.
Report date July 15, 2020 · Filed July 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2027-07-15 | Direct | 40,000 |
Reported balance
After 2020-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-15 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023.
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,622 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 42,622 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Travere Therapeutics, Inc.
Report date May 08, 2019 · Filed May 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,000 |
Reported balance
After 2019-05-08 transaction · row 1
1 source rowRow 1 · 2019-05-08 · Grant · Acquired 2,000 · Balance 29,000 |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.94 · Expires 2029-05-07 | Direct | 8,000 |
Reported balance
After 2019-05-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-05-08 · Grant · Acquired 8,000 · Balance 8,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 23:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,938 | $0.00 Strike: $237.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000098 · edgardoc.xml · derivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 836 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000098 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,622 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 13, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,575 | $0.00 Strike: $69.51 | $0.00 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · derivative · entry 11 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,575 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| May 13, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,575 | $223.50 | $352,012.50 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 9 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,786 Read SEC document |
| May 13, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,575 | $69.51 | $109,478.25 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 8 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 459 | $0.00 Strike: $69.51 | $0.00 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · derivative · entry 10 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,575 Underlying: Common Stock · 459 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2017, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| May 12, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 459 | $224.00 | $102,816.00 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 7 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,786 Read SEC document |
| May 12, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 459 | $69.51 | $31,905.09 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 6 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 116 | $234.09 | $27,153.89 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,786 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $233.6800 to $234.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 105 | $232.57 | $24,419.89 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,902 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $232.2000 to $232.9300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 165 | $231.87 | $38,258.07 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,007 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $231.1200 to $232.0700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1 | $229.87 | $229.87 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,172 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| May 01, 2026 Filed May 15, 2026 01:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 80 | $227.37 | $18,189.40 |
DisclosureSEC source: 0002001011-26-000049 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,173 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $227.1550 to $227.5800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 159 | $204.26 | $32,477.77 |
DisclosureSEC source: 0002001011-26-000038 · primary_doc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,253 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $204.0050 to $204.5400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 43 | $202.91 | $8,725.22 |
DisclosureSEC source: 0002001011-26-000038 · primary_doc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,412 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.8550 to $203.6550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 79 | $202.42 | $15,991.36 |
DisclosureSEC source: 0002001011-26-000038 · primary_doc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,455 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.0750 to $202.6400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 40 | $201.24 | $8,049.40 |
DisclosureSEC source: 0002001011-26-000038 · primary_doc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,534 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.0050 to $201.4650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 23:43 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 146 | $199.97 | $29,196.34 |
DisclosureSEC source: 0002001011-26-000038 · primary_doc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,574 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.6900 to $200.3150. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 42 | $203.57 | $8,549.94 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 6 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,720 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 50 | $202.54 | $10,126.94 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,762 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $202.1500 to $202.8700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 83 | $201.65 | $16,736.72 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,812 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $201.2150 to $202.0500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 41 | $200.40 | $8,216.56 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,895 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $200.1050 to $200.8400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 204 | $199.69 | $40,736.64 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,936 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.4100 to $200.0550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 02:04 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 47 | $197.14 | $9,265.57 |
DisclosureSEC source: 0002001011-26-000018 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,140 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.0650 to $197.2000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 23 | $197.20 | $4,535.49 |
DisclosureSEC source: 0002001011-26-000007 · edgardoc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,187 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 381 | $196.36 | $74,814.46 |
DisclosureSEC source: 0002001011-26-000007 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,210 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $196.0100 to $196.8400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 23 | $195.61 | $4,498.92 |
DisclosureSEC source: 0002001011-26-000007 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,591 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1 | $192.18 | $192.18 |
DisclosureSEC source: 0002001011-26-000007 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,614 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 39 | $191.00 | $7,449.00 |
DisclosureSEC source: 0002001011-26-000007 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,615 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 46 | $192.40 | $8,850.17 |
DisclosureSEC source: 0002001011-26-000004 · edgardoc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,654 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 207 | $190.27 | $39,385.95 |
DisclosureSEC source: 0002001011-26-000004 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,700 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $189.7800 to $190.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 102 | $188.96 | $19,274.20 |
DisclosureSEC source: 0002001011-26-000004 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,907 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $188.6000 to $189.3900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 91 | $187.95 | $17,103.78 |
DisclosureSEC source: 0002001011-26-000004 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,009 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $187.6150 to $188.5700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 21 | $186.59 | $3,918.39 |
DisclosureSEC source: 0002001011-26-000004 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,100 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 30 | $200.02 | $6,000.46 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 7 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,121 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $199.2800 to $200.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 23 | $199.22 | $4,581.95 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 6 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,151 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $198.2800 to $199.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 92 | $197.72 | $18,189.95 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 5 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,174 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $197.2800 to $198.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4 | $196.35 | $785.38 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,266 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $196.2800 to $197.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 47 | $195.80 | $9,202.54 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,270 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $195.2800 to $196.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 179 | $194.76 | $34,861.72 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,317 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $194.2800 to $195.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:08 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 92 | $193.86 | $17,834.91 |
DisclosureSEC source: 0002001011-25-000113 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,496 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $193.2800 to $194.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 127 | $192.38 | $24,432.02 |
DisclosureSEC source: 0002001011-25-000096 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,588 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $192.1200 to $192.9700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 207 | $191.25 | $39,588.63 |
DisclosureSEC source: 0002001011-25-000096 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,715 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $190.9400 to $191.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 49 | $190.26 | $9,322.64 |
DisclosureSEC source: 0002001011-25-000096 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,922 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $189.7800 to $190.5750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 84 | $189.00 | $15,875.73 |
DisclosureSEC source: 0002001011-25-000096 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,971 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $188.7150 to $189.5250. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 92 | $181.18 | $16,668.91 |
DisclosureSEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 4 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,055 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $180.9350 to $181.4000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 155 | $180.01 | $27,901.52 |
DisclosureSEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,147 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $179.4800 to $180.3100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 196 | $178.41 | $34,967.40 |
DisclosureSEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 2 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,302 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $177.8750 to $178.6400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 24 | $177.60 | $4,262.52 |
DisclosureSEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 1 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,498 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $176.6800 to $177.6450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:47 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 85 | $164.25 | $13,961.08 |
DisclosureSEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 3 KOZARICH JOHN W · CIK 0001223000 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,522 F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $163.9900 to $164.5000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.